Annovis Bio: CEO Shifts to CSO, New CMO Appointed
Ticker: ANVS · Form: 8-K · Filed: Aug 15, 2025 · CIK: 1477845
| Field | Detail |
|---|---|
| Company | Annovis Bio, Inc. (ANVS) |
| Form Type | 8-K |
| Filed Date | Aug 15, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-compensation, board-of-directors
TL;DR
Annovis Bio CEO Maccecchini is now CSO, Ezekowitz is new CMO. Leadership shuffle.
AI Summary
Annovis Bio, Inc. announced on August 11, 2025, changes in its board of directors and executive compensation. Dr. Maria Maccecchini, the CEO, will transition to the role of Chief Scientific Officer, while remaining on the board. Dr. Alan Ezekowitz has been appointed as the new Chief Medical Officer. The company also reported on its compensatory arrangements for certain officers.
Why It Matters
This filing indicates a strategic shift in leadership at Annovis Bio, with the CEO taking on a more scientific role and a new CMO being brought in, which could impact the company's research and development direction.
Risk Assessment
Risk Level: medium — Leadership changes, especially involving the CEO and CMO, can signal shifts in strategy or operational focus, introducing uncertainty.
Key Players & Entities
- Annovis Bio, Inc. (company) — Registrant
- Dr. Maria Maccecchini (person) — CEO transitioning to CSO
- Dr. Alan Ezekowitz (person) — Newly appointed Chief Medical Officer
- August 11, 2025 (date) — Date of earliest event reported
FAQ
What is the effective date of Dr. Maccecchini's transition to Chief Scientific Officer?
The filing does not specify an exact effective date for Dr. Maccecchini's transition to CSO, but it is reported as part of the events on or after August 11, 2025.
What are the specific details of the compensatory arrangements for the officers mentioned?
The filing states that information regarding compensatory arrangements of certain officers is included, but the specific details are not provided in this excerpt.
What is Dr. Alan Ezekowitz's prior experience relevant to his new role as CMO?
The provided text does not contain information about Dr. Alan Ezekowitz's prior experience.
Will Dr. Maccecchini continue to serve on the Board of Directors as CSO?
Yes, the filing states that Dr. Maria Maccecchini will remain on the board of directors in her new role as Chief Scientific Officer.
What is the primary reason cited for the leadership changes?
The filing does not explicitly state the primary reason for the leadership changes, but it is presented under 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers'.
Filing Stats: 493 words · 2 min read · ~2 pages · Grade level 12.4 · Accepted 2025-08-15 16:15:37
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ANVS New York Stock Exchang
Filing Documents
- tm2523187d1_8k.htm (8-K) — 25KB
- 0001104659-25-079248.txt ( ) — 188KB
- anvs-20250811.xsd (EX-101.SCH) — 3KB
- anvs-20250811_lab.xml (EX-101.LAB) — 33KB
- anvs-20250811_pre.xml (EX-101.PRE) — 22KB
- tm2523187d1_8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO, INC. Date: August 15, 2025 By: /s/ Maria Maccecchini Name: Maria Maccecchini Title: President and Chief Executive Officer